NCT04736355

DAOIB for the Treatment of Mild Cognitive Impairment

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 88 (actual)
• Sponsor: Chang Gung Memorial Hospital · Academic / Other
• Sex: All
• Age: 50 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

NMDA neurotransmission plays an important role in learning and memory. NMDA receptor-enhancing agent improved the cognitive function of patients with early-phase Alzheimer's disease. This study is a randomized, double-blind, placebo-controlled drug trial. All subjects will be allocated randomly to 2 groups: (1) DAOIB group; (2) placebo group. The study period is 24 weeks. The investigators hypothesize that DAOIB may yield better efficacy than placebo for cognitive function in patients with mild cognitive impairment.

Conditions

• Mild Cognitive Impairment

Interventions

Type	Name	Description
DRUG	DAOIB	oral, for 24 weeks
DRUG	Placebo	oral, for 24 weeks

Timeline

• Start date: 2020-01-01
• Primary completion: 2024-06-30
• Completion: 2024-06-30
• First posted: 2021-02-03
• Last updated: 2024-08-21

Locations

1 site across 1 country: Taiwan